Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
Historique:
received: 16 04 2019
revised: 13 06 2019
accepted: 13 06 2019
pubmed: 23 6 2019
medline: 5 8 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

Preclinical research suggests a role of Glucagon Like Peptide-1 Receptors (GLP-1R) on the regulation of human bronchial tone. We investigated the effect of GLP-1R agonists on lung function of Type 2 Diabetes Mellitus (T2DM) population without co-existing chronic obstructive respiratory disorders. This was a prospective cohort study that examined change in lung function measurements over two years of T2DM patients (n = 32) treated with metformin monotherapy (control cohort), metformin plus GLP-1R agonists (GLP-1R agonists cohort), or metformin plus insulin (insulin cohort). After 24 months of treatment, the forced expiratory volume in 1 s (FEV Our preliminary results suggest a potential new therapeutic perspective to treat airway disorders with GLP-1R agonists.

Identifiants

pubmed: 31228775
pii: S0954-6111(19)30205-7
doi: 10.1016/j.rmed.2019.06.015
pii:
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Insulin 0
Metformin 9100L32L2N

Types de publication

Clinical Trial Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-92

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Paola Rogliani (P)

Respiratory Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Maria Gabriella Matera (MG)

Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Luigino Calzetta (L)

Respiratory Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Electronic address: luigino.calzetta@uniroma2.it.

Nicola A Hanania (NA)

Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.

Clive Page (C)

Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, UK.

Immacolata Rossi (I)

Respiratory Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Aikaterini Andreadi (A)

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Angelica Galli (A)

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Angelo Coppola (A)

Respiratory Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Mario Cazzola (M)

Respiratory Unit, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Davide Lauro (D)

Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH